NASDAQ:RVPH Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis $1.27 +0.06 (+4.53%) (As of 02:35 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Reviva Pharmaceuticals Stock (NASDAQ:RVPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Reviva Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.18▼$1.2950-Day Range$0.92▼$1.5052-Week Range$0.60▼$5.67Volume222,422 shsAverage Volume384,255 shsMarket Capitalization$42.47 millionP/E RatioN/ADividend YieldN/APrice Target$15.50Consensus RatingBuy Company OverviewReviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Read More… Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Reviva Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks53rd Percentile Overall ScoreRVPH MarketRank™: Reviva Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 560th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingReviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageReviva Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Reviva Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.98) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Reviva Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Reviva Pharmaceuticals is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.85% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently decreased by 0.19%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldReviva Pharmaceuticals does not currently pay a dividend.Dividend GrowthReviva Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted15.85% of the outstanding shares of Reviva Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverReviva Pharmaceuticals has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in Reviva Pharmaceuticals has recently decreased by 0.19%, indicating that investor sentiment is improving. News and Social Media2.3 / 5News Sentiment0.22 News SentimentReviva Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders27.18% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Reviva Pharmaceuticals' insider trading history. Receive RVPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RVPH Stock News HeadlinesRVPH: Year-End OLE UpdateNovember 19 at 11:43 AM | msn.comReviva Pharmaceuticals Issues Financial Results and Business Outlook in Recent 8-K FilingNovember 16, 2024 | americanbankingnews.com917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”November 21, 2024 | Insiders Exposed (Ad)Reviva Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 14, 2024 | globenewswire.comReviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024November 6, 2024 | globenewswire.comReviva to Participate in the UBS Global Healthcare ConferenceOctober 31, 2024 | globenewswire.comReviva to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 8, 2024 | globenewswire.comReviva to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comSee More Headlines RVPH Stock Analysis - Frequently Asked Questions How have RVPH shares performed this year? Reviva Pharmaceuticals' stock was trading at $5.15 at the start of the year. Since then, RVPH stock has decreased by 75.6% and is now trading at $1.2550. View the best growth stocks for 2024 here. How were Reviva Pharmaceuticals' earnings last quarter? Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. Who are Reviva Pharmaceuticals' major shareholders? Reviva Pharmaceuticals' top institutional investors include Geode Capital Management LLC (0.83%). Insiders that own company stock include Prabhu Narayan and Purav Patel. View institutional ownership trends. How do I buy shares of Reviva Pharmaceuticals? Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Reviva Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL). Company Calendar Last Earnings8/14/2024Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RVPH CUSIPN/A CIK1742927 Webwww.revivapharma.com Phone(408) 501-8881FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$15.50 High Stock Price Target$17.00 Low Stock Price Target$14.00 Potential Upside/Downside+1,120.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,260,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-252.53% Debt Debt-to-Equity RatioN/A Current Ratio0.39 Quick Ratio0.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.30) per share Price / Book-4.23Miscellaneous Outstanding Shares33,440,000Free Float24,352,000Market Cap$42.47 million OptionableOptionable Beta-0.05 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:RVPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.